- TELA Bio Inc TELA has launched its second post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias.
- The study will enroll up to 100 subjects with patient follow-up at 90 days, 12 months, and 24 months.
- Study researchers will primarily monitor the incidence of early postoperative surgical site occurrences, wound-related events, and other complications within three months of surgery.
- Secondarily, researchers will monitor the incidence of true hernia recurrence, surgical site occurrences, and other complications occurring after three months post-surgery.
- Patient-reported outcomes will be evaluated and recorded using quality of life and pain assessments.
- Price Action: TELA shares closed at $13.43 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
